{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
NCT04396717: Phase 1 Interventional Completed Malignant Primary Brain Tumors
(2021)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02167854: Phase 1 Interventional Completed Breast Cancer
(2014)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00983658: Phase 2 Interventional Completed Asthma
(2009)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01966614: Phase 3 Interventional Completed Benign Prostatic Hyperplasia
(2013)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00866944: Phase 2 Interventional Completed Liver Metastases
(2009)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01098266: Phase 3 Interventional Completed Malignant Pleural Mesothelioma
(2010)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03100149: Phase 2 Interventional Active, not recruiting Parkinson's Disease
(2017)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00674466: Phase 2 Interventional Completed Type 2 Diabetes Mellitus
(2008)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:losatuxizumab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:mirvetuximab [INN]
Source URL:
Class:
PROTEIN
